Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Marker Therapeutics, Inc.
Report date October 16, 2018 · Filed October 17, 2018
Section 16 reporting ended · disclosed 2018-10-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,110 |
Reported balance
After 2018-10-16 transaction · row 1
1 source rowRow 1 · 2018-10-16 · Grant · Acquired 4,106 · Balance 36,110 F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2018 Filed Oct 17, 2018 12:50 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 4,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-054105 · tv504934_4.xml · nonDerivative · entry 1 Reddish Mark · CIK 0001547593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,110 F1 · shares: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 20:01 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 13,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-045902 · v474355_4.xml · nonDerivative · entry 1 Reddish Mark · CIK 0001547593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,004 F1 · shares: Represents the portion of the annual retainer for each non-employee director payable in immediately vested restricted, common stock under the Company's 2014 Omnibus Stock Ownership Plan and based on the closing price of $3.05 per share, on the day immediately preceding the date of the Company's 2017 annual meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.